NAD Press Releases

NAD Refers Advertising from RDK Global to FTC for Further Review

The National Advertising Division has referred to the Federal Trade Commission advertising claims made by RDK Global for the company’s Provailen dietary supplement after the company failed to provide a substantive response to an inquiry from NAD.

Read More

NAD Recommends Clorox Modify, Discontinue Certain Claims for Disinfecting Wipes Following Reckitt Benckiser Challenge

The National Advertising Division has recommended that The Clorox Company discontinue claims made for Clorox Disinfecting Wipes in broadcast and website advertising, in-store materials, and a Spanish-language radio commercial following a challenge by competitor Reckitt Benckiser, LLC.

Read More

DraftKings Commits to Discontinue Challenged Claims for Fantasy Sport Site

DraftKings, Inc., a fantasy sports website, has notified NAD that it will permanently discontinue claims that the site is the “#1” destination for daily fantasy sports on the Internet, as well as claims that it is “the industry leader” in daily fantasy sports.

Read More

NAD Recommends RB Discontinue Certain Claims for Mucinex Products, Company to Appeal

NAD has recommended that Reckitt Benckiser LLC discontinue certain advertising claims for the company’s Mucinex and Maximum Strength Mucinex chest congestion relievers, including claims that “Only Mucinex has a bi-layer tablet. One side starts fast in 8 minutes. The other side keeps on working for 12 hours.” RB has said it will appeal NAD’s findings to NARB.

Read More

NAD Finds Gerber Can Support Certain Claims Challenged by Nurture, Inc., Recommends Company Modify Claim for ‘Good Start Gentle Formula’

NAD found that Gerber Products Company could support advertising claims made on product packaging and in website advertising that various Gerber baby and toddler food products were a “good” or “excellent” source of certain nutrients. NAD recommended the company modify a claim made for Gerber Good Start Gentle Formula.

Read More

NAD Recommends Pursuit of Research Discontinue All Challenged Claims for Supplement Marketed as ‘Cures’ for Brain Injury, ADHD, Autism

NAD has recommended that Pursuit of Research, LLC, discontinue all challenged claims for the company’s Nutriiveda dietary supplements, which are marketed as “cures” for conditions that include attention deficit disorder, apraxia, autism, diabetes, dyspraxia, seizures, traumatic brain injury and stroke. The advertiser said it will appeal NAD’s decision to NARB.

Read More